{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:22:20Z","timestamp":1793766140993,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018439","name":"SK Life Science Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018439","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.seizure.2024.04.017","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T12:30:06Z","timestamp":1713789006000},"page":"95-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Efficacy and safety of adjunctive cenobamate based on patient etiology: Post-hoc analysis of YKP3089C017 randomized clinical trial"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6649-5722","authenticated-orcid":false,"given":"Jie","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9116-8857","authenticated-orcid":false,"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7769-9564","authenticated-orcid":false,"given":"Xiaorong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2024.04.017_bib0001","unstructured":"Epilepsy n.d. https:\/\/www.who.int\/health-topics\/epilepsy (accessed September 22, 2023)."},{"key":"10.1016\/j.seizure.2024.04.017_bib0002","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2024.04.017_bib0003","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.4103\/0972-2327.128644","article-title":"Approaches to refractory epilepsy","volume":"17","author":"Engel","year":"2014","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.seizure.2024.04.017_bib0004","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.seizure.2016.11.022","article-title":"Drug development for refractory epilepsy: the past 25 years and beyond","volume":"44","author":"Golyala","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2024.04.017_bib0005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/jamaneurol.2017.3069","article-title":"Questioning the effectiveness of newer antiseizure medications","volume":"75","author":"Hauser","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2024.04.017_bib0006","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","article-title":"Patterns of treatment response in newly diagnosed epilepsy","volume":"78","author":"Brodie","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2024.04.017_bib0007","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","article-title":"Quantifying the response to antiepileptic drugs: effect of past treatment history","volume":"70","author":"Schiller","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2024.04.017_bib0008","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2024.04.017_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106939","article-title":"Pharmacodynamic interactions of antiepileptic drugs: from bench to clinical practice","volume":"104","author":"Verrotti","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2024.04.017_bib0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.seizure.2024.04.017_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173117","article-title":"Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate","volume":"879","author":"Sharma","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.seizure.2024.04.017_bib0012","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2024.04.017_bib0013","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2024.04.017_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106592","article-title":"Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: a post-hoc analysis of a randomized clinical study","volume":"172","author":"Rosenfeld","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2024.04.017_bib0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.seizure.2022.02.003","article-title":"Efficacy and safety of adjunctive cenobamate: post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications","volume":"96","author":"Brandt","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2024.04.017_bib0016","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1474-4422(12)70018-2","article-title":"Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial","volume":"11","author":"Bonnett","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2024.04.017_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1684\/epd.2021.1255","article-title":"The aetiologies of epilepsy","volume":"23","author":"Balestrini","year":"2021","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2024.04.017_bib0018","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2024.04.017_bib0019","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/epi.12972","article-title":"Prevalence and etiology of epilepsy in a Norwegian county\u2014A population based study","volume":"56","author":"Syvertsen","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2024.04.017_bib0020","first-page":"e33301","article-title":"Prevalence of etiological factors in adult patients with epilepsy in a tertiary care hospital in the western region of Saudi Arabia: a cross-sectional study","volume":"15","author":"Makkawi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.seizure.2024.04.017_bib0021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yebeh.2014.02.032","article-title":"Seizure outcome after AED failure in pediatric focal epilepsy: impact of underlying etiology","volume":"34","author":"Wirrell","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2024.04.017_bib0022","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(98)03543-0","article-title":"Epileptology of the first-seizure presentation: a clinical, electroencephalographic, and magnetic resonance imaging study of 300 consecutive patients","volume":"352","author":"King","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2024.04.017_bib0023","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(06)70383-0","article-title":"Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial","volume":"5","author":"Kim","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2024.04.017_bib0024","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2024.04.017_bib0025","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/epi.12692","article-title":"WONOEP appraisal: new genetic approaches to study epilepsy","volume":"55","author":"Rossignol","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2024.04.017_bib0026","doi-asserted-by":"crossref","first-page":"40319","DOI":"10.1038\/srep40319","article-title":"Genetic variants identified from epilepsy of unknown etiology in Chinese children by targeted exome sequencing","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.seizure.2024.04.017_bib0027","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1528-1167.2010.02969.x","article-title":"A population-based study of long-term outcomes of cryptogenic focal epilepsy in childhood: cryptogenic epilepsy is probably not symptomatic epilepsy","volume":"52","author":"Wirrell","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2024.04.017_bib0028","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2024.04.017_bib0029","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","article-title":"The consequences of refractory epilepsy and its treatment","volume":"37","author":"Laxer","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2024.04.017_bib0030","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug\u2013drug interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2024.04.017_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108429","article-title":"Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures","volume":"126","author":"Privitera","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2024.04.017_bib0032","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/epi4.12757","article-title":"Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an expanded access program","volume":"8","author":"Villanueva","year":"2023","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.seizure.2024.04.017_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107796","article-title":"Cenobamate treatment of focal-onset seizures: quality of life and outcome during up to eight years of treatment","volume":"116","author":"Elizebath","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2024.04.017_bib0034","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/epi.17007","article-title":"Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study","volume":"62","author":"French","year":"2021","journal-title":"Epilepsia"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131124001225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131124001225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:11:57Z","timestamp":1762362717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131124001225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":34,"alternative-id":["S1059131124001225"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2024.04.017","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of adjunctive cenobamate based on patient etiology: Post-hoc analysis of YKP3089C017 randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2024.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}